Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.
We analysed the genetic changes in gp41 in a population of 30 heavily pretreated HIV-1-infected patients failing on a T-20-containing salvage therapy. This study confirms the key role of the number of drugs presumed to be still effective associated with T-20 in the magnitude of the virological response. Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required.
Marcelin
Anne-Geneviève
AG
Pitié-Salpêtrière Hospital, Paris, France.
Reynes
Jacques
J
Yerly
Sabine
S
Ktorza
Nadine
N
Segondy
Michel
M
Piot
Jean-Claude
JC
Delfraissy
Jean-François
JF
Kaiser
Laurent
L
Perrin
Luc
L
Katlama
Christine
C
Calvez
Vincent
V
D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D005814:Genes, Viral; D015700:HIV Envelope Protein gp41 / Q000235:genetics* / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1; D006801:Humans; D009154:Mutation; D010446:Peptide Fragments / Q000627:therapeutic use; D017434:Protein Structure, Tertiary; D017422:Sequence Analysis, DNA; D017211:Treatment Failure
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide